LUCI DAVID P 4

What Happened Luci David, President, CEO and Director of Acurx Pharmaceuticals (ACXP), was granted stock options to purchase 37,100 shares on April 20, 2026. The Form 4 reports the award as a derivative acquisition at $0.00 (no cash paid at grant). This is a compensation grant rather than an open‑market buy or sale.

Key Details

• Transaction (grant) date: 2026-04-20; Form 4 filed 2026-04-22 (timely).
• Instrument: Stock options to purchase 37,100 common shares (derivative transaction).
• Reported acquisition value on Form 4: $0.00 (common for option grants).
• Vesting: 36 equal monthly installments beginning on the grant date (per footnote).
• Shares owned after transaction: not specified in the filing.

Context This was an option award (future right to buy shares subject to vesting), not an exercise or sale. Such grants are routine executive compensation and do not indicate immediate buying or selling in the market.